Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 17,054 | 18,003 | 18,932 | 18,892 | 17,795 |
| Gross Profit | 17,054 | 18,003 | 18,932 | 18,892 | 17,795 |
| Operating Expenses | 49,820 | 52,889 | 49,962 | 55,605 | 57,246 |
| Operating Income | -32,766 | -34,886 | -31,030 | -36,713 | -39,451 |
| Interest Expense | 2,563 | 3,441 | 3,151 | 1,997 | 0 |
| Other Income | 3,809 | 4,298 | 4,664 | 3,866 | 1,837 |
| Pre-tax Income | -31,520 | -34,029 | -29,517 | -34,844 | -37,614 |
| Income Tax | -363 | -622 | -1,410 | 4,221 | 44 |
| Net Income Continuous | -31,157 | -33,407 | -28,107 | -39,065 | -37,658 |
| Net Income | $-31,157 | $-33,407 | $-28,107 | $-39,065 | $-37,658 |
| EPS Basic Total Ops | -1.47 | -1.58 | -1.34 | -1.86 | -1.79 |
| EPS Basic Continuous Ops | -1.47 | -1.58 | -1.34 | -1.86 | -1.79 |
| EPS Diluted Total Ops | -1.47 | -1.58 | -1.34 | -1.86 | -1.79 |
| EPS Diluted Continuous Ops | -1.47 | -1.58 | -1.34 | -1.86 | -1.79 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.58 | -1.33 | -1.86 | -1.79 |
| EBITDA(a) | $-32,120 | $-33,970 | $-30,425 | $-37,509 | $-39,917 |